Latest news with #DelveInsight
Malaysian Reserve
11 hours ago
- Business
- Malaysian Reserve
Claudin 18.2-Directed Oncology Therapeutics-A Fast-Growing Market with Blockbuster Potential
Claudin 18.2-directed therapies are on track to become foundational in the treatment of gastrointestinal and select solid tumors. Fueled by innovation in antibody engineering, combination strategies, and biomarker testing, this therapeutic class is set to play a transformative role in the next generation of precision oncology. LAS VEGAS, July 23, 2025 /PRNewswire/ — DelveInsight's Claudin 18.2 Directed Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as gastric cancer, pancreatic cancer, gastroesophageal junction adenocarcinoma, and other solid tumors. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging Claudin 18.2-directed therapies, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the Claudin 18.2 Directed Therapies Market Report As per DelveInsight's analysis, the total market size of Claudin 18.2-directed therapies in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as Gastric cancer, pancreatic cancer, gastroesophageal junction adenocarcinoma, and other solid tumors Leading Claudin 18.2-directed therapies companies, such as AskGene, Innovent, AstraZeneca, Antegene, Antennova, Kelun, Phanes, and others, are developing novel Claudin 18.2-directed therapies that can be available in the Claudin 18.2-directed therapies market in the coming years. Some of the key Claudin 18.2-directed therapies in the pipeline include ASKB589, IBI-343, AZD0901, ATG022/ATN022, SKB315, Spevatamig (PT886), and others. In May 2025, Astellas entered an exclusive license agreement with Evopoint Biosciences for XNW27011, a novel clinical-stage antibody-drug conjugate targeting CLDN18.2. Discover which indication is expected to grab the major Claudin 18.2-directed therapies market share @ Claudin 18.2 Directed Therapies Market Report Claudin 18.2 Directed Therapies Market Dynamics The Claudin 18.2-directed therapies market has been witnessing significant momentum driven by advancements in targeted oncology therapies. Claudin 18.2 is a tight junction protein selectively expressed in certain cancers, such as gastric cancer, gastroesophageal junction adenocarcinoma, and pancreatic cancer, making it an attractive therapeutic target. The approval of zolbetuximab (VYLOY) by Astellas has validated the clinical potential of Claudin 18.2-targeting monoclonal antibodies, positioning the pathway as a critical frontier in precision oncology. Other players, including domestic and international pharmaceutical companies, are actively developing monoclonal antibodies, antibody-drug conjugates (ADCs), and bispecific antibodies directed against Claudin 18.2, further intensifying the competitive dynamics. The market is characterized by a robust pipeline across various modalities. Monoclonal antibodies such as zolbetuximab lead the segment, but the pipeline also features novel ADCs and bispecifics, aiming to improve efficacy and overcome resistance mechanisms. Several companies are exploring combination regimens with checkpoint inhibitors and chemotherapy to enhance treatment outcomes. Additionally, there is a growing interest in expanding the therapeutic scope beyond gastric and gastroesophageal junction cancers to include pancreatic, lung, and other solid tumors where Claudin 18.2 expression is evident, potentially broadening the patient pool. Despite the growth prospects, the Claudin 18.2-directed therapies market faces several challenges. These include the need for reliable diagnostic tools to identify Claudin 18.2 expression, patient heterogeneity in expression levels, and potential off-target effects leading to safety concerns. Moreover, market penetration may be impacted by the high cost of biologics and the evolving reimbursement landscape, particularly in emerging markets. Nonetheless, the strong clinical efficacy signals, favorable regulatory momentum, and increasing physician awareness position Claudin 18.2 therapies for substantial growth over the next decade. Looking ahead, the Claudin 18.2-directed therapy landscape is expected to diversify with the introduction of next-generation modalities such as CAR-T therapies and vaccines targeting the protein. The competitive intensity is likely to increase as additional players enter late-stage development and as combination regimens redefine the treatment paradigm. Continued biomarker-driven patient selection and companion diagnostic development will be critical to optimizing outcomes and driving adoption. Overall, the Claudin 18.2 market represents a dynamic and evolving segment of the oncology therapeutics space, poised for continued innovation and expansion. Claudin 18.2 Directed Therapies Treatment Market Therapies targeting Claudin 18.2 have shown activity across several cancers, such as gastric cancer, pancreatic cancer, gastroesophageal junction adenocarcinoma, and other solid tumors. Astellas' VYLOY (zolbetuximab) is currently the first and only approved therapy directed against Claudin 18.2 for advanced gastric and gastroesophageal junction adenocarcinoma. It was first approved in Japan in March 2024, followed by regulatory clearance in the UK in August 2024, and later by the US FDA in October 2024. VYLOY is a cytolytic monoclonal antibody that targets claudin 18.2 and is approved for use alongside fluoropyrimidine- and platinum-based chemotherapy as a first-line treatment for adults with locally advanced, unresectable, or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma. This treatment is specifically intended for patients whose tumors express claudin 18.2, as confirmed by an FDA-approved diagnostic test. As a claudin 18.2-targeting cytolytic antibody, VYLOY destroys CLDN18.2-positive cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Preclinical models have shown that combining VYLOY with chemotherapy enhances antitumor activity in CLDN18.2-positive tumors compared to the use of either treatment alone. Learn more about the Claudin 18.2-directed therapies @ Claudin 18.2 Directed Therapies Analysis Key Emerging Claudin 18.2 Directed Therapies and Companies Several companies, including AskGene (ASKB589), Innovent (IBI-343), Antegene (ATG022/ATN022), Kelun (SKB315), AstraZeneca (AZD0901), Phanes (Spevatamig), and others, are currently engaged in the development and production of CLDN 18.2 therapies, which have the potential to significantly impact and enhance the MCR therapies market. ASKB589 is a humanized IgG1 monoclonal antibody targeting CLDN1, specifically designed to enhance antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). In combination with CAPOX chemotherapy and a PD-1 inhibitor as a first-line therapy for patients with gastric/gastroesophageal junction (G/GEJ) cancer, ASKB589 showed a favorable safety and tolerability profile. The addition of a PD-1 inhibitor to the ASKB589 plus CAPOX regimen in patients expressing moderate to high levels of CLDN18.2 led to promising anti-tumor effects, characterized by strong and lasting responses. IBI-343 is a recombinant human monoclonal antibody targeting Claudin 18.2, linked to a topoisomerase I inhibitor payload (Exatecan). Engineered with an Fc-silenced backbone to reduce unwanted immune activation, it features a cleavable linker for targeted drug release within tumor cells, enabling a bystander killing effect that affects neighboring tumor cells with low antigen expression. IBI-343 has been granted Fast Track Designation by the U.S. FDA and is currently being investigated in the Phase III G-HOPE trial (NCT06238843). The anticipated launch of these emerging therapies are poised to transform the Claudin 18.2-directed therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Claudin 18.2-directed therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about Claudin 18.2-directed therapies clinical trials, visit @ Claudin 18.2 Directed Therapies Treatment Claudin 18.2 Directed Therapies Overview Claudin 18.2 is a tight junction protein essential for preserving the integrity of the stomach lining. It is one of the two isoforms produced by the CLDN18 gene and is normally found only in differentiated epithelial cells of the gastric mucosa. In healthy tissues, Claudin 18.2 is hidden within tight junctions, making it inaccessible to drugs. However, during the development of cancers like gastric, gastroesophageal junction (GEJ), and pancreatic cancer, Claudin 18.2 becomes abnormally exposed on the surface of tumor cells, while its expression in normal tissues remains limited. This distinct expression profile makes Claudin 18.2 a promising and highly specific therapeutic target. The most advanced treatment targeting this protein is VYLOY, a monoclonal antibody that binds to Claudin 18.2 and induces immune-mediated killing of tumor cells. VYLOY has demonstrated encouraging results in late-stage clinical trials and is now approved for treating CLDN18.2-positive gastric and GEJ cancers. Additional therapies under investigation include CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Testing for CLDN18.2 expression using immunohistochemistry (IHC) helps identify patients who may benefit from these targeted treatments, highlighting the dual role of CLDN18.2 as both a biomarker and a therapeutic target in precision cancer therapy. Claudin 18.2 Directed Therapies Epidemiology Segmentation The Claudin 18.2-directed therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases of Selected Indications for Claudin 18.2-directed Therapies Total Eligible Patients of the Selected Indications of Claudin 18.2-directed Therapies Total Treated Cases in Selected Indications for Claudin 18.2-directed Therapies Claudin 18.2 Directed Therapies Report Metrics Details Study Period 2020–2034 Claudin 18.2 Directed Therapies Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Gastric cancer, pancreatic cancer, gastroesophageal junction adenocarcinoma, and other solid tumors Key Claudin 18.2 Directed Therapies Companies AskGene, Innovent, AstraZeneca, Antegene, Antennova, Kelun, Phanes, Astellas, and others Key Claudin 18.2 Directed Therapies ASKB589, IBI-343, AZD0901, ATG022/ATN022, SKB315, Spevatamig (PT886), VYLOY, and others Scope of the Claudin 18.2 Directed Therapies Market Report Claudin 18.2 Directed Therapies Therapeutic Assessment: Claudin 18.2 Directed Therapies current marketed and emerging therapies Claudin 18.2 Directed Therapies Market Dynamics: Conjoint Analysis of Emerging Claudin 18.2 Directed Therapies Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Claudin 18.2 Directed Therapies Market Access and Reimbursement Discover more about Claudin 18.2-directed therapies in development @ Claudin 18.2 Directed Therapies Clinical Trials Table of Contents 1 Key Insights 2 Report Introduction 3 Executive Summary of Claudin 18.2 Directed Therapies 4 Key Events 5 Epidemiology and Market Forecast Methodology 6 Claudin 18.2 Directed Therapies Market Overview at a Glance in the 7MM 6.1 Market Share (%) Distribution by Indication in 2024 6.2 Market Share (%) Distribution by Indication in 2034 6.3 Market Share (%) Distribution by Therapies in 2024 6.4 Market Share (%) Distribution by Therapies in 2034 7 Claudin 18.2 Directed Therapies: Background and Overview 8 Treatment and Management 9 Target Patient Pool 9.1 Key Findings 9.2 Assumptions and Rationale: 7MM 9.3 Epidemiology Scenario in the 7MM 9.3.1 Total Cases of Selected Indication for Claudin 18.2 Directed Therapies in the 7MM 9.3.2 Total Eligible Patient Pool for Claudin 18.2 Directed Therapies in Selected Indication in the 7MM 9.3.3 Total Treatable Cases in Selected Indications for Claudin 18.2 Directed Therapies in the 7MM 10 Marketed Therapies 10.1 Key Competitors 10.2 VYLOY (zolbetuximab): Astellas 10.2.1 Product Description 10.2.2 Regulatory milestones 10.2.3 Other developmental activities 10.2.4 Clinical development 10.2.5 Safety and efficacy List to be continued in the report… 11 Emerging Therapies 11.1 Key Competitors 11.2 ASKB589: AskGene 11.2.1 Product Description 11.2.2 Other developmental activities 11.2.3 Clinical development 11.2.4 Safety and efficacy 11.2.5 Analyst Views 11.3 IBI-343: Innovent 11.3.1 Product Description 11.3.2 Other developmental activities 11.3.3 Clinical development 11.3.4 Safety and efficacy 11.3.5 Analyst Views List to be continued in the report… 12 Claudin 18.2 Directed Therapies: Seven Major Market Analysis 12.1 Key Findings 12.2 Market Outlook 12.3 Conjoint Analysis 12.4 Key Market Forecast Assumptions 12.4.1 Cost Assumptions and Rebates 12.4.2 Pricing Trends 12.4.3 Analogue Assessment 12.4.4 Launch Year and Therapy Uptakes 12.5 Total Market Size of Claudin 18.2 Directed Therapies in the 7MM 12.6 The United States 12.7 EU4 and the UK 12.8 Japan 13 SWOT Analysis of Claudin 18.2 Directed Therapies 14 KOL Views of Claudin 18.2 Directed Therapies 15 Unmet Needs of Claudin 18.2 Directed Therapies 16 Market Access and Reimbursement 17 Bibliography 18 Report Methodology Related Reports Gastric Cancer Market Gastric Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key gastric cancer companies, including BeiGene, Linton Pharm Co. Ltd., RAPT Therapeutics, Leap Therapeutics, Idience, Bolt Biotherapeutics, Hubro Therapeutics, Immunocore, Ambrx, Hangzhou DAC Biotech, Beijing Immunoah Pharma Tech, Nanjing KAEDI Biotech, HiberCell, Transcenta Holding, Suzhou Zelgen Biopharmaceuticals, Daiichi Sankyo, Ipsen, Alligator Bioscience, Bristol Myers Squibb, Jiangsu Hengrui Medicine, Shanghai Junshi Biosciences, ImmunoACT, among others. Pancreatic Cancer Market Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pancreatic cancer companies, including AstraZeneca, Merck Sharp & Dohme LLC, Bayer, Roche, Celgene, Bristol Myers Squibb, BioLineRx, Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics, GlaxoSmithKline, Eleison Pharmaceuticals, Molecular Templates, Lokon Pharma AB, Cantargia AB, Bristol-Myers Squibb, among others. Gastroesophageal Junction Adenocarcinoma Market Gastroesophageal Junction Adenocarcinoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key gastroesophageal junction adenocarcinoma companies, including Astellas Pharmaceuticals, AstraZeneca, Bayer, Beigene, Bristol-Myers Squibb, Daichii Sankyo, Elevar Therapeutics, Eli Lilly, FivePrime Therapeutics, Incyte Corporation, Macrogenics, Merck Co., Ono Pharmaceuticals, Roche, Taiho Pharmaceuticals, Zai Labs, ZymeWorks, among others. Pancreatic Ductal Adenocarcinoma Market Pancreatic Ductal Adenocarcinoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PDAC companies, including Cardiff Oncology, Cantargia, RenovoRx, Jeil Pharmaceutical, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content:
Globe and Mail
12 hours ago
- Business
- Globe and Mail
Advanced Ovarian Cancer Clinical Trial Pipeline Spotlight: 50+ Companies Racing to Develop Safe and Effective Therapies
DelveInsight's, 'Advanced Ovarian Cancer Pipeline Insight 2025' report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Ovarian Cancer pipeline landscape. It covers the Advanced Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Ovarian Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Advanced Ovarian Cancer Pipeline Report to explore emerging therapies, key Companies, and future treatment landscapes @ Advanced Ovarian Cancer Pipeline Outlook Report Key Takeaways from the Advanced Ovarian Cancer Pipeline Report In July 2025, AstraZeneca announced a study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated. In July 2025, CanariaBio Inc. announced a study to compare the efficacy and safety of five administrations of oregovomab versus placebo, infused in schedule dependent sequence with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of patients with newly diagnosed advanced ovarian cancer who are planned to receive neoadjuvant treatment followed by interval debulking surgery (IDS) and adjuvant treatment. In July 2025, Incyte Corporation conducted a study is being conducted to evaluate the safety and tolerability of INCB099280 in combination with axitinib and to assess the antitumor activity of INCB099280 in combination with axitinib. This study will only be open in the UK and EU. DelveInsight's Advanced Ovarian Cancer pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Advanced Ovarian Cancer treatment. The leading Advanced Ovarian Cancer Companies such as OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc. and others. Promising Advanced Ovarian Cancer Pipeline Therapies such as Topotecan, Paclitaxel, Carboplatin, Bevacizumab, Erlotinib, AZD0530, Olaparib and others. Discover how the Advanced Ovarian Cancer treatment paradigm is evolving. Access DelveInsight's in-depth Advanced Ovarian Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Advanced Ovarian Cancer Clinical Trials and Studies Advanced Ovarian Cancer Emerging Drugs Profile Oregovomab: OncoQuest Oregovomab is a murine IgG against CA 125. Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in this phase II trial. In a randomized Phase II clinical trial of 97 patients, treatment with Oregovomab demonstrated a highly clinically significant outcome for both progression-free and overall survival favoring the addition of oregovomab to a standard of care chemotherapy combination of carboplatin and paclitaxel. The risk of progression and of death was reduced by more than 50% when compared to placebo, and safety data showed that oregovomab did not add incremental toxicity to the chemotherapy regimen. Stenoparib: Allarity Therapeutics Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. It is currently in Phase 2 testing for ovarian cancer with patients selected by the Stenoparib DRP. The Stenoparib DRP® is validated for ovarian cancer. It is currently being evaluated for the treatment of advanced ovarian cancer in a Phase 2 clinical trial at the Dana-Farber Cancer Institute using the Stenoparib DRP® companion diagnostic to guide patient enrollment and improve therapeutic outcome. DP-303c: CSPC ZhongQi Pharmaceutical Technology Co., Ltd. DP-303c is under development for the treatment of HER2 low expressing solid tumors, gastric cancer including gastroesophageal junction, breast cancer, adenocarcinoma of the gastroesophageal junction, epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The drug candidate is an antibody drug conjugate that is administered by intravenous route. It acts by targeting human epidermal growth factor receptor 2 (HER2). The Advanced Ovarian Cancer pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Advanced Ovarian Cancer with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Advanced Ovarian Cancer Treatment. Advanced Ovarian Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Advanced Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Advanced Ovarian Cancer market. Get a detailed analysis of the latest innovations in the Advanced Ovarian Cancer pipeline. Explore DelveInsight's expert-driven report today! @ Advanced Ovarian Cancer Unmet Needs Advanced Ovarian Cancer Companies OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc. and others. Advanced ovarian cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Parenteral Intravenous Subcutaneous Topical. Advanced Ovarian Cancer Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Download DelveInsight's latest report to gain strategic insights into upcoming Advanced Ovarian Cancer Therapies and key Developments @ Advanced Ovarian Cancer Market Drivers and Barriers, and Future Perspectives Scope of the Advanced Ovarian Cancer Pipeline Report Coverage- Global Advanced Ovarian Cancer Companies- OncoQuest, Allarity Therapeutics, AstraZeneca, Jiangxi Qingfeng Pharmaceutical Co. Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Ellipses Pharma, Merck KGaA, Pfizer, Jiangsu HengRui Medicine Co., Ltd., Puma Biotechnology, Inc., Bayer, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Daiichi Sankyo, Inc., Astellas Pharma Inc. and others. Advanced Ovarian Cancer Pipeline Therapies- Topotecan, Paclitaxel, Carboplatin, Bevacizumab, Erlotinib, AZD0530, Olaparib and others. Advanced Ovarian Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Advanced Ovarian Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Advanced Ovarian Cancer drug development? Find out in DelveInsight's exclusive Advanced Ovarian Cancer Pipeline Report—access it now! @ Advanced Ovarian Cancer Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Advanced ovarian cancer: Overview Pipeline Therapeutics Therapeutic Assessment Advanced ovarian cancer – DelveInsight's Analytical Perspective In-depth Commercial Assessment Advanced ovarian cancer Collaboration Deals Late Stage Products (Phase III) Oregovomab: OncoQuest Drug profiles in the detailed report….. Mid Stage Products (Phase II) Stenoparib - Allarity Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) DS-6000a: Daiichi Sankyo Company Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Advanced ovarian cancer Key Companies Advanced ovarian cancer Key Products Advanced ovarian cancer- Unmet Needs Advanced ovarian cancer- Market Drivers and Barriers Advanced ovarian cancer- Future Perspectives and Conclusion Advanced ovarian cancer Analyst Views Advanced ovarian cancer Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth Curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Business Upturn
16 hours ago
- Health
- Business Upturn
Global Dysmenorrhea Treatment Market to Cross ~USD 8 Billion by 2032
New York, USA, July 23, 2025 (GLOBE NEWSWIRE) — Global Dysmenorrhea Treatment Market to Cross ~USD 8 Billion by 2032 | DelveInsight The rising occurrence of dysmenorrhea, along with greater awareness and advancements in diagnosis, is driving substantial growth in the dysmenorrhea treatment market. With more women pursuing medical care for menstrual discomfort, there is a growing demand for a wide range of treatment options, including over-the-counter painkillers and hormonal therapies. Furthermore, awareness campaigns and educational initiatives are playing a key role in breaking the stigma around the condition, promoting earlier diagnosis and treatment. DelveInsight's Dysmenorrhea Treatment Market Insights report provides the current and forecast market analysis, individual leading dysmenorrhea treatment companies' market shares, challenges, dysmenorrhea treatment market drivers, barriers, trends, and key market dysmenorrhea treatment companies in the market. Key Takeaways from the Dysmenorrhea Treatment Market Report As per DelveInsight estimates, North America is anticipated to dominate the global dysmenorrhea treatment market during the forecast period. In the treatment segment of the dysmenorrhea treatment market, the devices category accounted for the largest market share in 2024. Notable dysmenorrhea treatment companies such as Johnson & Johnson Services Inc., iPulse Medical Ltd., Bridges CHC, LLC., AbbVie Inc., Myoovi Ltd., Rael Inc., Abbott, Pfizer Inc., TensCare Ltd. (UK), Beurer GmbH (Germany), BPL Medical Technologies, Cora, Carex Health Brands (USA), Sumitovant Biopharma, Emcure Pharmaceuticals, Everteen, Samphire Neuroscience, Mirapulse, Welme, Nomisk, and several others are currently operating in the dysmenorrhea treatment market. and several others are currently operating in the dysmenorrhea treatment market. In September 2024, Organon K.K., a global healthcare company focused on women's health, announced that it had achieved the primary endpoint in a domestic Phase III clinical trial evaluating the efficacy and safety of OG-8276A for dysmenorrhea. Based on the trial results, the company prepared to apply for marketing approval and launch in Japan. To read more about the latest highlights related to the dysmenorrhea treatment market, get a snapshot of the key highlights entailed in the Global Dysmenorrhea Treatment Market Report Dysmenorrhea Treatment Overview Dysmenorrhea, commonly known as menstrual cramps, is managed through a combination of pharmacological and non-pharmacological treatments aimed at relieving pain and improving quality of life. First-line pharmacological therapies typically include nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen and naproxen, which work by reducing prostaglandin production, one of the main causes of uterine contractions and pain during menstruation. For individuals who do not respond adequately to NSAIDs or have more severe symptoms, hormonal therapies like combined oral contraceptives, progestin-only pills, hormonal intrauterine devices (IUDs), or contraceptive implants may be prescribed to regulate or suppress ovulation and lessen menstrual flow, thereby reducing pain. In cases of secondary dysmenorrhea, where an underlying condition such as endometriosis or fibroids is present, treatment may be more complex and involve surgical interventions or disease-specific therapies. Non-pharmacological approaches also play an important role in dysmenorrhea management. Lifestyle modifications such as regular exercise, stress reduction, and dietary changes, like reducing caffeine and fat intake, may help alleviate symptoms. Heat therapy (using heating pads or hot baths), acupuncture, yoga, and transcutaneous electrical nerve stimulation (TENS) are complementary therapies that some individuals find beneficial. Additionally, education and counseling can empower individuals to better manage their symptoms and seek timely medical intervention when needed. As awareness about menstrual health grows, there is an increasing emphasis on personalized treatment approaches that consider the individual's medical history, symptom severity, and lifestyle preferences. Dysmenorrhea Treatment Market Insights North America dominated the dysmenorrhea treatment market in 2024, supported by several critical drivers. The region benefits from a well-established healthcare system, heightened awareness of menstrual health issues, and a growing adoption of advanced medical technologies. There has been a notable increase in the demand for non-invasive and drug-free therapies, such as TENS devices, heat therapy products, and wearable pain relief solutions. Furthermore, an increasing emphasis on women's health, favorable regulatory policies, and rising investments in R&D for innovative menstrual pain management solutions are fueling market growth. Moreover, the presence of leading companies like iPulse Medical, the manufacturer of Livia, an FDA-approved wearable device utilizing TENS to offer immediate relief from menstrual cramps, demonstrates how technological advancements and consumer demand for convenient, non-drug solutions are propelling the U.S. market. As a result, these factors are expected to significantly drive the growth of the dysmenorrhea treatment market in North America over the forecast period from 2025 to 2032. To know more about why North America is leading the market growth in the dysmenorrhea treatment market, get a snapshot of the Dysmenorrhea Treatment Market Outlook Dysmenorrhea Treatment Market Dynamics The dysmenorrhea treatment market is witnessing robust growth, driven by the rising prevalence of menstrual disorders and the increasing focus on women's health globally. Dysmenorrhea, characterized by painful menstruation, is highly prevalent among adolescent girls and women of reproductive age. This large patient base creates significant demand for effective treatment options. Over-the-counter (OTC) medications such as NSAIDs, prescription hormonal therapies like oral contraceptives, and newer non-pharmacological options such as transcutaneous electrical nerve stimulation (TENS) and dietary supplements form the current market landscape. Additionally, a growing interest in personalized and integrative approaches, including acupuncture and lifestyle modifications, is adding further diversity to the treatment landscape. Market dynamics are also shaped by increasing awareness and the gradual destigmatization of menstrual health issues. Educational campaigns, better diagnosis rates, and healthcare provider initiatives are encouraging more women to seek treatment rather than endure symptoms in silence. This positive shift in societal attitudes is contributing to a higher diagnosis rate and, consequently, expanding the market for dysmenorrhea therapies. Moreover, digital health platforms and telemedicine services are improving access to gynecological consultations, particularly in emerging markets, where access to specialized care was traditionally limited. On the competitive front, the market features a mix of established pharmaceutical companies, consumer healthcare brands, and emerging startups. While OTC NSAIDs remain the first-line therapy, the hormonal therapy segment is gaining traction due to its dual benefits of contraception and menstrual pain management. However, hormonal treatments are associated with side effects and contraindications, prompting a surge in research and development activities for novel, safer, and more targeted therapeutics. Startups and wellness brands are also tapping into consumer demand for natural and plant-based solutions, further intensifying market competition. Despite its growth potential, the dysmenorrhea treatment market faces certain challenges. Barriers such as high costs of advanced hormonal therapies, limited insurance coverage in some regions, and cultural stigmas in conservative societies can hinder treatment uptake. Furthermore, many women opt for home remedies or endure the pain without seeking medical intervention, limiting the addressable market. Ongoing clinical trials for novel non-hormonal therapies and personalized medicine approaches hold promise, but these therapies may take time to gain regulatory approvals and widespread acceptance. In summary, the dysmenorrhea treatment market is poised for steady growth, supported by a large patient base, increasing awareness, and a broadening range of treatment options. Strategic partnerships, R&D investments, and patient education will play pivotal roles in overcoming existing barriers and unlocking further growth opportunities in this market. As the focus on women's health continues to rise globally, the market is expected to see continued innovation and diversification in treatment modalities. Get a sneak peek at the dysmenorrhea treatment market dynamics @ Dysmenorrhea Treatment Market Trends Report Metrics Details Coverage Global Study Period 2022–2032 Dysmenorrhea Treatment Market CAGR ~7% Dysmenorrhea Treatment Market Size by 2032 ~USD 8 Billion Key Dysmenorrhea Treatment Companies Johnson & Johnson Services Inc., iPulse Medical Ltd., Bridges CHC, LLC., AbbVie Inc., Myoovi Ltd., Rael Inc., Abbott, Pfizer Inc., TensCare Ltd. (UK), Beurer GmbH (Germany), BPL Medical Technologies, Cora, Carex Health Brands (USA), Sumitovant Biopharma, Emcure Pharmaceuticals, Everteen, Samphire Neuroscience, Mirapulse, Welme, Nomisk, among others Dysmenorrhea Treatment Market Assessment Dysmenorrhea Treatment Market Segmentation Dysmenorrhea Treatment Market Segmentation By Type: Primary Dysmenorrhea and Secondary Dysmenorrhea Dysmenorrhea Treatment Market Segmentation By Route of Treatment: Drugs, Devices, and Others Dysmenorrhea Treatment Market Segmentation By End-User: Hospitals, Gynecology & Wellness Clinics, and Homecare Settings Dysmenorrhea Treatment Market Segmentation By Geography : North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the dysmenorrhea treatment market are set to emerge as the trendsetter explore @ Dysmenorrhea Treatment Options Table of Contents 1 Dysmenorrhea Treatment Market Report Introduction 2 Dysmenorrhea Treatment Market Executive Summary 3 Competitive Landscape 4 Regulatory Analysis 5 Dysmenorrhea Treatment Market Key Factors Analysis 6 Dysmenorrhea Treatment Market Porter's Five Forces Analysis 7 Dysmenorrhea Treatment Market Layout 8 Dysmenorrhea Treatment Market Company and Product Profiles 9 KOL Views 10 Project Approach 11 About DelveInsight 12 Disclaimer & Contact Us Interested in knowing the dysmenorrhea treatment market by 2032? Click to get a snapshot of the Dysmenorrhea Treatment Market Analysis Related Reports Dysmenorrhea Market Dysmenorrhea Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dysmenorrhea companies, including Daewon Pharmaceutical, PNB Vesper Life Science, Nobelpharma, among others. Dysmenorrhea Pipeline Dysmenorrhea Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dysmenorrhea companies, including Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corporation, Sanofi, MediciNova, Helixmith, Verge Genomics, UCB, among others. Non-Steroidal Anti-Inflammatory Drugs Market Non-Steroidal Anti-Inflammatory Drugs Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key NSAIDs companies, including Pfizer Inc., Johnson & Johnson Services, Inc., Bayer AG, Sanofi, GSK plc., Heron Therapeutics, Inc., Strides Pharma Science Limited, Sun Pharmaceutical Industries Ltd., Reckitt Benckiser Group PLC., Assertio Holdings, Inc., AstraZeneca, Boehringer Ingelheim Ltd., Assertio Holdings, Inc., Horizon Therapeutics plc, Perrigo Company plc, Viatris Inc., Dr. Reddy's Laboratories Ltd., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Eli Lilly and Company, among others. Contraceptives Market Contraceptives Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key contraceptives companies, including Teva Pharmaceutical Industries Ltd, TherapeuticsMD, Inc., AbbVie Inc., Bayer AG, The Cooper Companies Inc., FemCap Inc, Veru Inc., Meril Life Sciences Pvt. Ltd., Pregna International Limited., Reckitt Benckiser Group PLC., Viatris Inc., EUROGINE, S.L, Gedeon Richter Plc., Agile Therapeutics., Evofem Biosciences, Inc., Amneal Pharmaceuticals LLC., Shanghai Dahua Pharmaceutical Co., Ltd., Pfizer Inc., Contech Devices Private Limited, Cupid Limited, among others. Menstrual Cups Market Menstrual Cups Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key menstrual cups companies, including Redcliffe Hygiene Private Limited, The Keeper, Inc., Lena Cup, INTIMINA, Blossom Cup, Mooncup Ltd, PEPTONIC Medical, YUUKI Company s.r.o., Anigan, LadyCup, Me Luna GmbH, The Flex Company, Procter & Gamble, Diva International Inc., Saalt, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Globe and Mail
a day ago
- Business
- Globe and Mail
Cystic Fibrosis Pipeline Outlook 2025: Insights into Drug Development and Leading 50+ Companies
DelveInsight's, ' Cystic fibrosis Pipeline Insight, 2025 ' report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Cystic fibrosis pipeline landscape. It covers the Cystic Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cystic Fibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Cystic Fibrosis Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Cystic Fibrosis Pipeline Outlook Report Key Takeaways from the Cystic Fibrosis Pipeline Report In July 2025, Enterprise Therapeutics Ltd announced a study is the first to give ETD001 to people with CF. The study will be run in two parts. Part A will assess if ETD001 is safe to give to people with CF, and Part B will assess if ETD001 improves lung function. The study drug is taken twice a day, in Part A it is taken for 7 days and in Part B for 28 days. In Part B there will be a separate period where dummy medicine is given for 28 days so the treatments can be compared. In July 2025, Vertex Pharmaceuticals Incorporated conducted a study is to evaluate the pharmacokinetics, safety, tolerability and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in CF participants with at least 1 triple combination responsive (TCR) mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. DelveInsight's Cystic Fibrosis pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Cystic Fibrosis treatment. The leading Cystic Fibrosis Companies such as Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant Sciences, Vertex Pharmaceuticals, Krystal Biotech, Porosome Therapeutics, SpliSense, Enterprise Therapeutics Ltd and others. Promising Cystic fibrosis Pipeline Therapies such as Tigerase®, Pulmozyme®, danazol, Brensocatib, SPL84, ETD001, ELX/TEZ/IVA, BI 3720931, JBT-101 (lenabasum) and others. Discover how the Cystic Fibrosis treatment paradigm is evolving. Access DelveInsight's in-depth Cystic Fibrosis Pipeline Analysis for a closer look at promising breakthroughs @ Cystic Fibrosis Clinical Trials and Studies Cystic Fibrosis Emerging Drugs Profile VX-121: Vertex Pharmaceuticals VX-121 and tezacaftor are designed to increase the amount of mature protein at the cell surface by targeting the processing and trafficking defect of the CFTR protein. VX-561 (deutivacaftor) is a potentiator designed to keep CFTR proteins at the cell surface open longer to improve the flow of salt and water across the cell membrane, which helps hydrate and clear mucus from the airways. The triple combination of VX-121/tezacaftor/VX-561 is being developed as an investigational once-daily treatment for people with CF with certain mutations in the CFTR gene. It is currently being investigated in Phase III stage of development. Brensocatib: AstraZeneca Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase I (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. The drug is currently being evaluated in Phase II clinical trial to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of study drug. ELX-02: Eloxx Pharmaceuticals ELX-02 is an investigational compound being developed as a therapy for genetic diseases caused by nonsense mutations such as cystic fibrosis. Structurally, ELX-02 is an aminoglycoside analogue that induces read-through of nonsense mutations through interaction with the ribosome, resulting in the production of full-length functional proteins. The therapy was designated an orphan drug in the US, an orphan medicinal product in Europe, and given fast track designation in the US. ELX-02 is being tested in CF patients carrying least one G542X mutation in two parallel open-label Phase II clinical trials. S-1226: SolAeroMed Inc. S1226 is SolAeroMed's lead therapy. S1226 is formulated to rapidly reopen constricted, mucus plugged airways, and should increase the effectiveness of respiratory drug delivery. The S1226 formulation consists of aerosolized carbon dioxide (CO2) and nebulized perflubron; which is delivered into the lung. The delivery of this formulation results in an immediate relaxant effect on the patient's constricted airways, supported by a lowering of surface tension in inflamed areas (resulting in enhanced bronchial dilation) and possible clearing of mucus plugs of blocked airways. SolAeroMed is currently conducrting a phase II clinical trial in cystic fibrosis. The Cystic Fibrosis Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Cystic Fibrosis with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cystic Fibrosis Treatment. Cystic Fibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Cystic Fibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cystic Fibrosis market Explore groundbreaking therapies and clinical trials in the Cystic Fibrosis Pipeline. Access DelveInsight's detailed report now! @ New Cystic Fibrosis Drugs Cystic Fibrosis Companies Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant Sciences, Vertex Pharmaceuticals, Krystal Biotech, Porosome Therapeutics, SpliSense, Enterprise Therapeutics Ltd and others. Cystic fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Cystic Fibrosis Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Cystic Fibrosis Market Drivers and Barriers, and Future Perspectives Scope of the Cystic Fibrosis Pipeline Report Coverage- Global Cystic Fibrosis Companies- Verona Pharma, Armata Pharmaceuticals, 4D Molecular Therapeutics, Spirovant Sciences, Vertex Pharmaceuticals, Krystal Biotech, Porosome Therapeutics, SpliSense, Enterprise Therapeutics Ltd and others. Cystic fibrosis Pipeline Therapies- Tigerase®, Pulmozyme®, danazol, Brensocatib, SPL84, ETD001, ELX/TEZ/IVA, BI 3720931, JBT-101 (lenabasum) and others. Cystic Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Cystic Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Cystic Fibrosis drug development? Find out in DelveInsight's exclusive Cystic Fibrosis Pipeline Report—access it now! @ Cystic Fibrosis Emerging Drugs and Major Companies Table of Content Introduction Executive Summary Cystic Fibrosis: Overview Pipeline Therapeutics Therapeutic Assessment Cystic Fibrosis – DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug name: Company Name Drug profiles in the detailed report….. Mid-Stage Products (Phase II) AP-PA02: Armata Pharmaceuticals Drug profiles in the detailed report….. Early Stage Products (Phase I) VX-522: Vertex Pharmaceuticals Drug profiles in the detailed report….. Preclinical and Discovery Stage Products SPL23: SpliSense Drug profiles in the detailed report….. Inactive Products Cystic Fibrosis -Key Companies Cystic Fibrosis -Key Products Cystic Fibrosis - Unmet Needs Cystic Fibrosis - Market Drivers and Barriers Cystic Fibrosis - Future Perspectives and Conclusion Cystic Fibrosis -Analyst Views Cystic Fibrosis- Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Business Upturn
2 days ago
- Business
- Business Upturn
Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity
New York, USA, July 22, 2025 (GLOBE NEWSWIRE) — Melanoma Market Anticipates a Dynamic Shift During the Forecast Period (2025–2034) Owing to the Strong Pipeline Activity | DelveInsight The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launch of emerging therapies such as Lerapolturev (Istari Oncology), Nidlegy (Philogen), GIM-531 (Georgiamune), DOC-1021 (Diakonos Oncology), IMA203 (Immatics Biotechnologies), and others, heightened UV exposure, advancements in diagnostic techniques, and lifestyle changes. DelveInsight's Melanoma Market Insights report includes a comprehensive understanding of current treatment practices, emerging melanoma drugs, market share of individual therapies, and current and forecasted Melanoma market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. Key Takeaways from the Melanoma Market Report According to DelveInsight's analysis, the total melanoma market size is expected to grow positively by 2034. The United States accounts for the largest market size of melanoma, in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan. In 2024, the total number of incident cases of melanoma was approximately 105K in the US. The trend indicates that melanoma occurs more frequently in males than in females, and around 20% of cases eventually progress to advanced stages (stage III/IV), involving unresectable or distant metastatic disease. in the US. The trend indicates that melanoma occurs more frequently in males than in females, and around of cases eventually progress to advanced stages (stage III/IV), involving unresectable or distant metastatic disease. Prominent companies, including Istari Oncology, Philogen, Georgiamune, Diakonos Oncology, Immatics Biotechnologies, Replimune, BMS, Ascentage Pharma, Erasca, Krystal Biotech, IDEAYA Biosciences, Novartis, HUYA Bioscience, Regeneron Pharmaceuticals, and others, are actively working on innovative melanoma drugs. and others, are actively working on innovative melanoma drugs. Some of the key melanoma therapies in the pipeline include Lerapolturev, Nidlegy, GIM-531, DOC-1021, IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, APG-115, Naporafenib (ERAS-254), KB707, Darovasertib (IDE196), HBI-8000, Fianlimab , and others. These novel melanoma therapies are anticipated to enter the melanoma market in the forecast period and are expected to change the market. , and others. These novel melanoma therapies are anticipated to enter the melanoma market in the forecast period and are expected to change the market. In May 2025, Immatics announced the presentation of expanded data from the ongoing Phase Ib clinical trial evaluating IMA203 in heavily pretreated patients with metastatic melanoma announced the presentation of expanded data from the ongoing Phase Ib clinical trial evaluating IMA203 in heavily pretreated patients with metastatic melanoma In April 2025, IDEAYA Biosciences announced a successful FDA Type D meeting on the Phase III registrational trial design that would assess the safety and efficacy of darovasertib for potential regulatory approval as neoadjuvant therapy for primary uveal melanoma. Discover which melanoma medications are expected to grab the market share @ Melanoma Market Report Melanoma Overview Melanoma is a type of skin cancer that originates in melanocytes, the pigment-producing cells responsible for giving skin its color. While it is less common than other skin cancers, melanoma is significantly more aggressive and has a higher risk of spreading to other parts of the body if not detected early. It can occur anywhere on the body but is most frequently found on areas exposed to the sun, such as the back, legs, arms, and face. The primary cause of melanoma is ultraviolet radiation from sunlight or artificial sources like tanning beds, which can damage the DNA in skin cells. Individuals with fair skin, a history of sunburns, a large number of moles, or a family history of melanoma are at higher risk. Genetic mutations, such as in the BRAF gene, also play a significant role in the development of melanoma in certain cases. Symptoms of melanoma often begin with changes in the appearance of a mole or pigmented area. Warning signs include asymmetry, irregular borders, color variation, a diameter larger than 6 mm, and evolving shape or size, summarized by the ABCDE rule. Itching, bleeding, or the appearance of a new mole can also be concerning signs. Diagnosis typically involves a thorough skin examination followed by a biopsy of any suspicious lesion. If melanoma is confirmed, further tests such as sentinel lymph node biopsy, imaging scans (CT, MRI, or PET), and blood work may be conducted to determine the stage and whether the cancer has spread. Early diagnosis is critical, as it significantly improves the prognosis and expands treatment options. Melanoma Epidemiology Segmentation The melanoma epidemiology section provides insights into the historical and current melanoma patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders. The melanoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Incident Cases of Melanoma Stage-specific Incident Cases of Melanoma Mutation-specific Incident Cases of Melanoma Line-wise Treated Cases of Melanoma Download the report to understand which factors are driving melanoma epidemiology trends @ Melanoma Treatment Algorithm Melanoma Treatment Market There remains a substantial unmet need for effective treatment options in melanoma patients who are resistant to, unsuitable for, or unresponsive to standard therapies like checkpoint inhibitors or BRAF/MEK-targeted treatments. The FDA has approved several therapies for melanoma, including AMTAGVI (lifileucel, Iovance Biotherapeutics), OPDUALAG (nivolumab + relatlimab, Bristol Myers Squibb), KEYTRUDA (pembrolizumab, Merck), OPDIVO (nivolumab, BMS), KIMMTRAK (tebentafusp-tebn, Immunocore), YERVOY (ipilimumab, BMS), TECENTRIQ (atezolizumab, Roche), among others. AMTAGVI, from Iovance Biotherapeutics, became the first FDA-approved, personalized, one-time T cell therapy in February 2024. It is intended for adults with unresectable or metastatic melanoma who have previously been treated with PD-1 inhibitors, and for those with BRAF V600 mutations, after BRAF inhibitor ± MEK inhibitor therapy. That same year, Iovance submitted a Marketing Authorization Application (MAA) for lifileucel to the EMA in June (validated in August) and to the UK's MHRA in October. In June 2025, Iovance announced that the final results from the Phase II C-144-01 trial of AMTAGVI in advanced melanoma patients were published in the Journal of Clinical Oncology and presented at the 2025 ASCO Annual Meeting. Bristol Myers Squibb's OPDUALAG combines nivolumab, a PD-1 inhibitor, with relatlimab, a LAG-3 inhibitor, and is indicated for the treatment of unresectable or metastatic melanoma. The FDA approved it in March 2022 for adults and children aged 12 and above. However, in February 2025, BMS reported that the Phase III RELATIVITY-098 trial did not achieve its primary endpoint of recurrence-free survival (RFS) in the adjuvant setting for completely resected stage III–IV melanoma, although the safety profile remained consistent with existing data on the combination. KEYTRUDA and OPDIVO both demonstrate strong efficacy in treating melanoma, though OPDIVO has gained greater commercial traction through effective combination regimens and broader clinical use. Despite metastatic melanoma often being incurable, the emergence of advanced treatments such as immune checkpoint inhibitors and targeted therapies has markedly improved survival and quality of life, signaling a significant evolution in the standard of care. Learn more about the melanoma treatment options @ Melanoma Treatment Guidelines Melanoma Emerging Drugs and Companies Some of the products in the pipeline include Lerapolturev (Istari Oncology), Nidlegy (Philogen), GIM-531 (Georgiamune), DOC-1021 (Diakonos Oncology), IMA203 (Immatics Biotechnologies), RP1 (vusolimogene oderparepvec) plus nivolumab (Replimune and BMS), APG-115 (Ascentage Pharma), Naporafenib (ERAS-254) (Erasca), KB707 (Krystal Biotech), Darovasertib (IDE196) (IDEAYA Biosciences and Novartis), HBI-8000 (HUYA Bioscience and BMS), Fianlimab (Regeneron Pharmaceuticals), and others. IMA203 is a TCR T-cell therapy that targets the Preferentially Expressed Antigen in Melanoma (PRAME). It's designed to identify an intracellular PRAME-derived peptide displayed on the surface of cells by HLA-A*02:01, triggering a strong and specific anti-tumor immune response. Encouraging Phase Ib results, along with PRAME's high expression rate in melanoma (~90–95%), support IMA203's therapeutic promise. The therapy is currently under investigation in the SUPRAME Phase III trial (NCT06743126) for previously treated advanced or metastatic cutaneous melanoma, and its Phase Ib expansion now includes uveal melanoma. According to the company's 2024 Annual Report, interim analysis for IMA203 is expected in Q1 2026, with final Phase III results in Q4 2026. A Biologics License Application (BLA) submission is planned for Q1 2027, aiming for a market launch in Q3 2027. RP1 is a herpes simplex virus-based therapy modified with a fusogenic protein (GALV-GP R) and GM-CSF to enhance tumor cell destruction, increase immunogenic cell death, and promote a systemic anti-tumor immune response. The FDA has awarded Breakthrough Therapy Designation (BTD) for RP1 in combination with nivolumab for adults with advanced melanoma that has progressed after anti-PD1 treatment. In June 2025, Replimune shared updated results from the IGNYTE study (RP1 + nivolumab in anti-PD1-refractory melanoma) at the 2025 ASCO Annual Meeting. Darovasertib (IDE196) is a potent, selective PKC inhibitor in clinical development. PKC lies downstream of the GNAQ and GNA11 pathways. Darovasertib is currently in a Phase III trial for primary non-metastatic uveal melanoma, a Phase II/III (DAR-UM-2) study for HLA-A2-negative metastatic uveal melanoma (MUM), and other Phase II trials in ocular melanoma. The company expects results from the pivotal DAR-UM-2 trial in first-line HLA-A2-negative MUM by late 2025. In March 2025, the FDA granted BTD to darovasertib for neoadjuvant treatment of primary uveal melanoma patients recommended for enucleation. The anticipated launch of these emerging melanoma therapies are poised to transform the Melanoma market landscape in the coming years. As these cutting-edge melanoma therapies continue to mature and gain regulatory approval, they are expected to reshape the melanoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about new treatment for melanoma, visit @ Melanoma Management Melanoma Market Dynamics The melanoma market dynamics are anticipated to change in the coming years. Drugs like OPDIVO and KEYTRUDA, particularly in combination with ipilimumab, have significantly improved overall survival and achieved durable response rates (~30–40%) in metastatic melanoma; however, the limited long-term efficacy in many patients highlights the urgent need for effective second-line therapies and continued innovation. With nearly 50% of melanoma patients harboring BRAF mutations, targeted therapy has become a viable option, while molecular profiling enables patient stratification even in refractory settings for clinical trials and off-label interventions. Moreover, targeting underrepresented melanoma subtypes such as uveal, mucosal, and acral presents opportunities for market expansion and accelerated regulatory pathways, given the high unmet need and paucity of existing therapies. Furthermore, many potential therapies are being investigated for the treatment of melanoma, and it is safe to predict that the treatment space will significantly impact the melanoma market during the forecast period. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the diagnosis rate is expected to drive the growth of the melanoma market in the 7MM. However, several factors may impede the growth of the melanoma market. Moreover, melanoma treatment poses a significant economic burden and disrupts patients' overall well-being and QOL. Furthermore, the melanoma market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the melanoma market growth. Melanoma Report Metrics Details Study Period 2020–2034 Melanoma Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Melanoma Companies Istari Oncology, Philogen, Georgiamune, Diakonos Oncology, Immatics Biotechnologies, Replimune, BMS, Ascentage Pharma, Erasca, Krystal Biotech, IDEAYA Biosciences, Novartis, HUYA Bioscience, Regeneron Pharmaceuticals, and others Key Melanoma Therapies Lerapolturev, Nidlegy, GIM-531, DOC-1021, IMA203, RP1 (vusolimogene oderparepvec) plus nivolumab, APG-115, Naporafenib (ERAS-254), KB707, Darovasertib (IDE196), HBI-8000, Fianlimab, and others Scope of the Melanoma Market Report Melanoma Therapeutic Assessment: Melanoma current marketed and emerging therapies Melanoma current marketed and emerging therapies Melanoma Market Dynamics: Conjoint Analysis of Emerging Melanoma Drugs Conjoint Analysis of Emerging Melanoma Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, Melanoma Market Access and Reimbursement Discover more about melanoma drugs in development @ Melanoma Clinical Trials Table of Contents 1. Melanoma Market Key Insights 2. Melanoma Market Report Introduction 3. Melanoma Market Overview at a Glance 4. Melanoma Market Executive Summary 5. Disease Background and Overview 6. Melanoma Treatment and Management 7. Melanoma Epidemiology and Patient Population 8. Patient Journey 9. Melanoma Marketed Drugs 10. Melanoma Emerging Drugs 11. Seven Major Melanoma Market Analysis 12. Melanoma Market Outlook 13. Potential of Current and Emerging Therapies 14. KOL Views 15. Unmet Needs 16. SWOT Analysis Related Reports Melanoma Pipeline Melanoma Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key melanoma companies, including IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, among others. Ocular Melanoma Market Ocular Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ocular melanoma companies, including Bristol Myers Squibb, Merck & Co., Inc., Novartis AG, Roche Holding AG, Pfizer Inc., AstraZeneca PLC, Eli Lilly and Company, Bayer AG, GlaxoSmithKline PLC, Amgen Inc., among others. Uveal Melanoma Market Uveal Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key uveal melanoma companies, including Novartis Pharmaceuticals, Foghorn Therapeutics, TriSalus Life Sciences, Inc., Bristol Myers Squibb, Array BioPharma, Ono Pharmaceutical, AstraZeneca, Roche, IDEAYA Biosciences, Merck & Co, GlaxoSmithKline, Janssen, among others. Metastatic Melanoma Market Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic melanoma companies, including Cancer Insight LLC, Elios Therapeutics LLC, Evaxion Biotech A/S, Merck Sharp & Dohme LLC, Novartis Pharmaceuticals, InxMed (Shanghai) Co. Ltd., Aivita Biomedical Inc., Hoffmann-La Roche, Idera Pharmaceuticals, Iovance Biotherapeutics Inc., Eisai Inc., Biocad, Myrexis Inc., Pain Therapeutics, Altor BioScience, among others. Refractory Metastatic Melanoma Market Refractory Metastatic Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key refractory metastatic melanoma companies, including BioNTech SE, Y-mAbs Therapeutics, Seagen Inc., among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Pharmaceutical Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Connect with us on LinkedIn|Facebook|Twitter Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
